Title:
METHODS AND KITS FOR PREDICTING A RESPONSE TO AN ERYTHROPOIETIC AGENT
Document Type and Number:
WIPO Patent Application WO/2011/163506
Kind Code:
A3
Abstract:
Methods for predicting a response to an erythropoietic agent in a subject include providing a biological sample from the subject, and determining an amount in the sample of at least one peptide selected from the group consisting of SEQ ID NOS: 1-17. If there is a measurable difference in the amount of the at least one peptide in the sample, when compared to a control level of the same peptide, the subject is then predicted to have a good response or a poor response to the erythropoietic agent. Kits for predicting a response to an erythropoietic agent are further provided and include one or more antibodies, or fragments thereof, that specifically recognize a peptide of SEQ ID NOS: 1-17.
Inventors:
MERCHANT MICHAEL L (US)
KLEIN JON (US)
BRIER MICHAEL E (US)
GAWEDA ADA (US)
KLEIN JON (US)
BRIER MICHAEL E (US)
GAWEDA ADA (US)
Application Number:
PCT/US2011/041674
Publication Date:
August 09, 2012
Filing Date:
June 23, 2011
Export Citation:
Assignee:
UNIV LOUISVILLE RES FOUND (US)
MERCHANT MICHAEL L (US)
KLEIN JON (US)
BRIER MICHAEL E (US)
GAWEDA ADA (US)
MERCHANT MICHAEL L (US)
KLEIN JON (US)
BRIER MICHAEL E (US)
GAWEDA ADA (US)
International Classes:
G01N33/68; G01N33/15; G01N33/53
Domestic Patent References:
| WO2009046313A2 | 2009-04-09 |
Other References:
M. AAPRO ET AL.: "Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient- related variables: results from the Anemia Cancer Treatment (ACT) study.", ANNALS OF ONCOLOGY., vol. 20, no. 20, 2009, pages 1714 - 1721
DATABASE GENBANK 3 May 1996 (1996-05-03), "fibrinogen N term Bern II", accession no. 912289A
TILMAN STEINMETZ ET AL.: "Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors.", THE ONCOLOGIST., vol. 12, no. 6, 2007, pages 748 - 755
R. STASI ET AL.: "Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.", ANNALS OF ONCOLOGY., vol. 16, no. 12, 2005, pages 1921 - 1927
CECILIA T. COSTINIUK ET AL.: "Erythropoiesis-Stimulating Agent Use for Anemia Induced by Interferon-Ribavirin Treatment in Patients with Hepatitis C Virus Infection Is Not Associated with Increased Rates of Cardiovascular Disease, Thrombosis, Malignancy, or Death.", CLINICAL INFECTIOUS DISEASES., vol. 47, no. 2, 2008, pages 198 - 202
DATABASE GENBANK 3 May 1996 (1996-05-03), "fibrinogen N term Bern II", accession no. 912289A
TILMAN STEINMETZ ET AL.: "Prediction of the Responsiveness to Treatment with Erythropoiesis-Stimulating Factors: A Prospective Clinical Study in Patients with Solid Tumors.", THE ONCOLOGIST., vol. 12, no. 6, 2007, pages 748 - 755
R. STASI ET AL.: "Darbepoetin alfa for the treatment of anemic patients with low- and intermediate-1-risk myelodysplastic syndromes.", ANNALS OF ONCOLOGY., vol. 16, no. 12, 2005, pages 1921 - 1927
CECILIA T. COSTINIUK ET AL.: "Erythropoiesis-Stimulating Agent Use for Anemia Induced by Interferon-Ribavirin Treatment in Patients with Hepatitis C Virus Infection Is Not Associated with Increased Rates of Cardiovascular Disease, Thrombosis, Malignancy, or Death.", CLINICAL INFECTIOUS DISEASES., vol. 47, no. 2, 2008, pages 198 - 202
Attorney, Agent or Firm:
WRIGHT, Terry L. et al. (400 West Market StreetSuite 180, Louisville Kentucky, US)
Download PDF:
Previous Patent: OCULAR IMPLANTS DEPLOYED IN SCHLEMM'S CANAL OF THE EYE
Next Patent: ADAPTIVE PATIENT INTERFACE
Next Patent: ADAPTIVE PATIENT INTERFACE